Ginger Capsules for the Chronic Treatment of Obesity
Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition in the Obesity Treatment and Improvement Behavioral Profile
1 other identifier
interventional
84
1 country
1
Brief Summary
Regarding its complex pathogenesis and clinic-epidemiological meaning, different strategies are needed for the treatment of obesity. Ginger is the rhizome of a plant with thermogenic and anti-inflammatory effects, and may be a promising alternative as add-on strategy in the treatment for obesity. The primary objective of the current study is to assess whether consumption of ginger as an add-on strategy to restrictive diet is effective to reduce fat body percentage, increase basal metabolic rate and improve loss weight. The secondary objectives are:
- to assess the effect of nutritional intervention in quality of diet and weight loss.
- to evaluate the effect of ginger on behavioral symptoms and peripheral biomarkers in overweight subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2 obesity
Started Aug 2015
Typical duration for phase_2 obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 5, 2016
CompletedFirst Posted
Study publicly available on registry
April 18, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2018
CompletedApril 18, 2016
April 1, 2016
3.3 years
February 5, 2016
April 13, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in basal metabolic rate.
Ginger effect in basal metabolic rate will be measured by calorimetry.
Baseline and 30, 60, 90, 120, 150 and 180 days
Change in body fat percentage.
Ginger effect in body fat percentage will be measured by bioimpedance.
Baseline and 30, 60, 90, 120, 150 and 180 days
Secondary Outcomes (7)
Changes in serum levels of inflammatory mediators
Baseline and 30, 60, 90, 120, 150 and 180 days
Change in depressive symptoms.
Baseline and 30, 60, 90, 120, 150 and 180 days
Change in anxiety symptoms.
Baseline and 30, 60, 90, 120, 150 and 180 days
Change in quality of life.
Baseline and 30, 60, 90, 120, 150 and 180 days
Change in perceived stress.
Baseline and 30, 60, 90, 120, 150 and 180 days
- +2 more secondary outcomes
Study Arms (2)
Placebo
PLACEBO COMPARATORConventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
Ginger group
EXPERIMENTALConventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
Interventions
Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
Eligibility Criteria
You may qualify if:
- Women aged 18-60 years old;
- Body mass index 25-35 kg/m².
You may not qualify if:
- Pregnant or lactating women;
- Abuse of alcohol or drugs;
- Hypersensitivity to ginger;
- Other endocrine disease;
- Women in use of insulin or anti-inflammatory and antidepressants drugs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital das Clínicas
Belo Horizonte, Minas Gerais, 30130-100, Brazil
Related Publications (5)
van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW. Longitudinal relationship of depressive and anxiety symptoms with dyslipidemia and abdominal obesity. Psychosom Med. 2013 Jan;75(1):83-9. doi: 10.1097/PSY.0b013e318274d30f. Epub 2012 Nov 28.
PMID: 23197842BACKGROUNDAtashak S, Peeri M, Azarbayjani MA, Stannard SR, Haghighi MM. Obesity-related cardiovascular risk factors after long- term resistance training and ginger supplementation. J Sports Sci Med. 2011 Dec 1;10(4):685-91. eCollection 2011.
PMID: 24149559BACKGROUNDChrubasik S, Pittler MH, Roufogalis BD. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine. 2005 Sep;12(9):684-701. doi: 10.1016/j.phymed.2004.07.009.
PMID: 16194058BACKGROUNDGregersen NT, Belza A, Jensen MG, Ritz C, Bitz C, Hels O, Frandsen E, Mela DJ, Astrup A. Acute effects of mustard, horseradish, black pepper and ginger on energy expenditure, appetite, ad libitum energy intake and energy balance in human subjects. Br J Nutr. 2013 Feb 14;109(3):556-63. doi: 10.1017/S0007114512001201. Epub 2012 Jul 5.
PMID: 23021155BACKGROUNDSaravanan G, Ponmurugan P, Deepa MA, Senthilkumar B. Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. J Sci Food Agric. 2014 Nov;94(14):2972-7. doi: 10.1002/jsfa.6642. Epub 2014 Apr 7.
PMID: 24615565BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Adaliene VM Ferreira, PhD
Federal University of Minas Gerais
- STUDY CHAIR
Nayara M Monteze, Ma
Federal University of Minas Gerais
- PRINCIPAL INVESTIGATOR
Antônio L Teixeira, PhD
Federal University of Minas Gerais
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
February 5, 2016
First Posted
April 18, 2016
Study Start
August 1, 2015
Primary Completion
November 1, 2018
Study Completion
November 1, 2018
Last Updated
April 18, 2016
Record last verified: 2016-04
Data Sharing
- IPD Sharing
- Will not share